BMI vs XYL: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
XYL is the larger of the two ($21.75B market cap): the incumbent the market prices for continued execution (16.27x forward earnings, beta 0.99). BMI is the smaller challenger ($4.52B), actually pricier on forward earnings (31.24x): more room to run, but more to prove. If you believe BMI earns its premium (31.24x forward earnings, so the market expects more from it), BMI fits. If you believe in paying less for profit, XYL fits at 16.27x.
BMI vs XYL: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BMI | XYL | What it tells you |
|---|---|---|---|
| Market cap | $4.52B | $21.75B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 31.24 | 16.27 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 35.98 | 21.03 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.62 | 0.99 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 58% of range | 13% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 6.83 | 2.13 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: XYL is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how BMI and XYL affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMI and XYL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMI and XYL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Badger Meter (BMI) do?
Badger Meter designs and sells water meters, flow-measurement instruments, and the radio and software layer (ORION and GALAXY radios, BEACON and OneNetwork software, and the broader BlueEdge portfolio) that turns municipal water systems into connected networks. Its core customers are North American water utilities upgrading from manual reads to automated meter reading (AMR) and advanced metering infrastructure (AMI), where cellular AMI is the gateway to leak detection, usage analytics, and recurring, high-margin SaaS revenue that compounds on top of the hardware installed base.
What does Xylem (XYL) do?
Xylem was spun out of ITT in 2011 and has become the largest publicly traded pure-play water technology company, operating through four segments: Water Infrastructure (transport and treatment for utilities), Applied Water (pumps and equipment for building and industrial use), Measurement and Control Solutions (smart meters, sensors and the Sensus platform), and Water Solutions and Services (the outsourced treatment and services business built up by the 2023 Evoqua acquisition). Its customers are heavily weighted toward water and wastewater utilities plus industrial users, which gives it exposure to non-discretionary, regulation-driven spending on aging pipes, leak detection, metering and treatment.
BMI vs XYL: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- BMI drivers: Cellular AMI installed base; Recurring software and SaaS attach.
- XYL drivers: Aging infrastructure and water scarcity; Digital water and smart metering.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Near-term results are exposed to the timing of large utility AMI projects and to weaker short-cycle order rates, which pushed Q1 2026 EPS well below consensus and left revenue down year over year in Q1 and Q2; Q3 revenue was only flat and slightly below estimates. For XYL, organic growth has been flat to negative in recent quarters, and that concern has already cost the stock: third-quarter 2026 revenue fell ~3% year over year, shares are down ~31% in 2026 as of November 20, and several analysts cut price targets in October on fears of sustained top-line pressure, so even a lower multiple leaves room for disappointment if utility or industrial demand slows.
BMI or XYL: which should you pick?
If the story you believe is BMI's (Cellular AMI installed base), BMI is the more direct way to own it; if it is XYL's (Aging infrastructure and water scarcity), XYL is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMI and XYL guides.
BMI vs XYL: the full fundamentals
BMI. At about $155 per share on November 20, 2026, Badger Meter trades near 36 times trailing earnings and 31 times forward estimates, a richer multiple than in October after a 14% three-month rebound. Consensus expects 2026 EPS of about $4.47 (down about 7%) before rising about 12% to roughly $4.99 in 2027, so the price assumes growth returns next year. The eight analysts in Yahoo's consensus carry a mean target near $166 and a buy rating.
XYL. Xylem still earns a premium to many industrials, but the multiple has compressed from the mid-30s in June to about 21 times trailing earnings in November, as the market weighs steady margins against revenue that fell ~3% in the third quarter. Analysts expect ~$5.43 of EPS for 2026 and ~$5.83 for 2027, which puts the forward multiple near 16, and the average target of 16 analysts is ~$125. The fourth-quarter consensus is ~$1.42 of EPS on ~$2.3 billion of revenue.
Headline figures (approximate, November 2026): BMI shows revenue (ttm) ~$881M (Q3 2026 ~flat YoY), q3 2026 revenue / eps ~$236M / $1.24 (vs $1.22 est.), net income (ttm) ~$127M (~14% net margin), margins (gross / operating) ~42% / ~19%; XYL shows revenue (ttm) ~$9.1B; Q3 2026 ~$2.20B, down ~3% YoY, margins gross ~39%, operating ~16%, net ~12%, net income (ttm) ~$1.1B; Q3 2026 adjusted EPS ~$1.44 vs ~$1.45 expected, p/e trailing / forward ~21x / ~16x.
The bottom line: BMI vs XYL
BMI and XYL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined BMI and XYL exposure against your real portfolio. It is not an investment adviser.
Wondering how BMI or XYL fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Badger Meter
Ask Walnut's AI anything about BMI and see how it fits what you own.
FAQ
What is the difference between BMI and XYL?
+
Badger Meter designs and sells water meters, flow-measurement instruments, and the radio and software layer (ORION and GALAXY radios, BEACON and OneNetwork software, and the broader BlueEdge portfolio) that turns municipal water systems into connected networks. Xylem was spun out of ITT in 2011 and has become the largest publicly traded pure-play water technology company, operating through four segments: Water Infrastructure (transport and treatment for utilities), Applied Water (pumps and equipment for building and industrial use), Measurement and Control Solutions (smart meters, sensors and the Sensus platform), and Water Solutions and Services (the outsourced treatment and services business built up by the 2023 Evoqua acquisition). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BMI or XYL the better stock?
+
Neither is universally better. XYL is the larger incumbent; BMI is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BMI or XYL?
+
On forward P/E (as of November 2026), BMI trades at 31.24x and XYL at 16.27x, so XYL is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BMI and XYL?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BMI vs XYL?
+
BMI: Near-term results are exposed to the timing of large utility AMI projects and to weaker short-cycle order rates, which pushed Q1 2026 EPS well below consensus and left revenue down year over year in Q1 and Q2; Q3 revenue was only flat and slightly below estimates. After a roughly 14% rebound over three months, the stock carries a premium valuation (about 36 times trailing and 31 times forward earnings), so growth disappointment in 2027 can drive more multiple compression. Competition is intense from larger and well-capitalized rivals including Xylem (Sensus), Roper (Neptune), Mueller, and Itron, which can pressure pricing and share. Supply-chain costs, tariffs, and component availability can squeeze gross margins, and integration risk accompanies acquisitions like UDlive and 37South, the latter in a new country for the company. Utility budgets and municipal funding cycles add cyclicality to an otherwise steady end market. XYL: Organic growth has been flat to negative in recent quarters, and that concern has already cost the stock: third-quarter 2026 revenue fell ~3% year over year, shares are down ~31% in 2026 as of November 20, and several analysts cut price targets in October on fears of sustained top-line pressure, so even a lower multiple leaves room for disappointment if utility or industrial demand slows. A large share of revenue depends on municipal and utility budgets that can be delayed by funding cycles, elections or macro pressure, and softer metering sales show that risk in the numbers. The company carries acquisition-related debt (~$3.0 billion against ~$0.7 billion of cash) and goodwill from the Evoqua deal, and integration or synergy shortfalls would weigh on margins. Xylem also has meaningful international exposure, adding currency and regional demand risk. Finally, competition in metering and treatment from focused players can pressure pricing in specific product lines.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BMI or XYL; figures are approximate and dated (as of November 2026). Verify current data before investing.